Chengdu-based adeno-associated virus (AAV) gene therapy developer, Genevector Biotechnology Co., Ltd., has announced the first patient dosing in a clinical study for its product candidate, JWK001. The molecule is under assessment as a potential treatment for neovascular age-related macular degeneration (nAMD).
JWK001’s Mechanism of Action and Preclinical Performance
JWK001 employs AAV technology to deliver a newly designed VEGF neutralizing protein expression sequence to retinal cells. By continuously expressing VEGF neutralizing protein at high levels, JWK001 efficiently binds to vascular growth factors, thereby inhibiting the process of neovascularization. Preclinical studies have demonstrated that JWK001 injections offer advantages such as a low effective dose and favorable safety profile.
Comparative Efficacy and Dosing of JWK001
When compared with REGENXBIO’s RGX-314, which is in the clinical I/IIa stage, JWK001 is reported to achieve higher in vivo expression levels with fewer injection doses. This suggests that Genevector’s therapy may provide a more efficient treatment option for patients suffering from nAMD.-Fineline Info & Tech
